Serum of transthyretin as a treatment-responsive biomarker for schizophrenia

Brain and Nerve

Volumn 65, Issue 9, 2013, Pages 1093-1099

  Nakagawa, Nobuaki ^a   Yao, Hiroshi ^a   Nakahara, Tatsuo ^a   Inomata, Shinsaku ^a   Hashimoto, Kijiro ^a   Kuroki, Toshihide ^a  

^a National Hospital Organization Hizen Psychiatric Center   (Japan)

Author keywords

Biomarker; Proteomics; Schizophrenia; SELDI TOF MS; Serum

Indexed keywords

BIOLOGICAL MARKER; PREALBUMIN;

ARTICLE; DOWN REGULATION; DYNAMICS; ENZYME LINKED IMMUNOSORBENT ASSAY; ISOELECTRIC POINT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PROTEIN ANALYSIS; PROTEOMICS; SCHIZOPHRENIA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PEPTIDE MAPPING; PREALBUMIN; PROTEOMICS; SCHIZOPHRENIA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84884303159     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Matsuzaki S, Tohyama M: Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia. Expert Opin Ther Targets 12: 1097-1108, 2008
2. Mayilyan KR, Weinberger DR, Sim RB: The complement system in schizophrenia. Drug News Perspect 21: 200-210, 2008
3. Heikkilä L, Rimón R, Terenius L: Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 34: 229-236, 1990
4. Yang Y, Wan C, Li H, Zhu H, La Y, et al: Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78: 3571-3576, 2006
5. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, et al: Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3: e428, 2006
6. Yao H, Nakahara T, Nakagawa N, Hashimoto K, Kuroki T: Regional and temporal changes in proteomic profile after middle cerebral artery occlusion with or without reperfusion in rats. Neurochem Res 34: 1999-2007, 2009
7. Fleming CE, Nunes AF, Sousa MM: Transthyretin: more than meets the eye. Prog Neurobiol 89: 266-276, 2009
8. Su F, Lang J, Kumar A, Ng C, Hsieh B, et al: Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2: 369-375, 2007
9. Suzuyama K, Shiraishi T, Oishi T, Ueda S, Okamoto H, et al: Combined proteomic approach with SELDI-TOF-MS and peptide mass fingerprinting identified the rapid increase of monomeric transthyretin in rat cerebrospinal fluid after transient focal cerebral ischemia. Brain Res Mol Brain Res 129: 44-53, 2004
10. Ryan WG, Roddam RF, Grizzle WE: Thyroid function screening in newly admitted psychiatric inpatients. Ann Clin Psychiatry 6: 7-12, 1994
11. Ruano D, Macedo A, Soares MJ, Valente J, Azevedo MH, et al: Transthyretin: no association between serum levels or gene variants and schizophrenia. J Psychiatr Res 41: 667-672, 2007